Paris

• Efficacy of tocilizumab in the treatment of acute anterior ischemic optic neuropathy optic neuropathy in Horton's disease Ended
  2024-519977-20-00 4 2025-01-27 Acute Anterior Ischemic Optic Neuropathy associated with Giant Cell Ar
• M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors Ended
  2023-505431-12-00 1 2025-01-20 Patients with pretreated, metastatic or locally advanced cancer for th
• A study to test how well BI 3720931 is tolerated and whether it improves lung function in people with cystic fibrosis (LenticlairTM 1) Ended
  2023-503281-23-00 7 2024-12-19 Cystic fibrosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children Wit … Ended
  2024-513129-22-00 5 2024-12-17 Hypochondroplasia
• A randomized, open-label, controlled phase III trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab … Ended
  2024-513697-22-00 5 2024-11-07 non-small-cell lung cancer
• Multicenter randomized controlled trial of the value of intravitreal anti-VEGF injections as initial then adjuvant treatment in Coats' disea … Ended
  2024-517036-21-00 4 2024-11-06 Coats' disease
• A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended
  2023-507563-19-00 5 2024-11-05 Thyroid eye disease
• Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin … Ended
  2024-516435-27-00 4 2024-11-05 High-risk myeloïd malignancies
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic
• SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended
  2024-513648-27-00 4 2024-10-25 Patients with newly or active diffuse Systemic sclerosis (SSc) at the
• KONFIDENT-KID Ended
  2023-507591-44-00 5 2024-10-24 Hereditary Angioedema Type I or II
• Impact of 18F-FES TEP on therapeutical management in patients with metastatic breast cancer, ER positive and HER2 negative, in relapse after … Ended
  2024-517400-11-00 6 2024-10-24 Patients with metastatic breast cancer initially presenting with overe
• A safety and efficacy study of ARGX-119 in adult patients with Amyotrophic Lateral Sclerosis (ALS) (reALiSe) Ended
  2024-511318-19-00 4 2024-10-23 Amyotrophic Lateral Sclerosis (ALS)
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509198-22-00 5 2024-10-21 Thyroid Eye Disease (TED)
• Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome Ended
  2023-509638-20-00 4 2024-09-30 Alport Syndrome
• A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease Ended
  2023-506805-20-01 5 2024-09-25 Neurodegenerative Diseases
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended
  2024-511225-64-00 4 2024-09-18 Alopecia areata
• A study of aficamten (CK-3773274) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA) Ended
  2023-505797-15-00 5 2024-09-13 SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
• PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease Ended
  2024-513647-86-00 4 2024-09-09 Patients displaying a non-classified, severe and resistant inflammator
• Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, … Ended
  2024-516299-13-00 4 2024-09-06 Resectable Gastric Cancer
• Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease Ended
  2023-507892-23-00 4 2024-08-30 Charcot-Marie-Tooth Disease Type 1 and Type 2
• A Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Infigratinib in Children with Achondroplasia Ended
  2023-506130-67-00 5 2024-08-20 Achondroplasia
• A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended
  2023-508821-28-00 4 2024-08-14 Migraine
• European randomised clinical trial on mPOX Infection (EPOXI) Ended
  2022-501979-10-00 6 2024-08-08 Monkeypox

Showing 1,873–1,896 of 2,286 trials